Marshall Wace’s Journey Medical DERM Stock Holding History

Marshall Wace’s Portfolio DERM Stock Details DERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,401	Closed	-$150K	–	3297
2025 Q4	$150K	Buy	+19,401	New	+$152K	﹤0.01%	2649

Other funds holding DERM

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

PFCS

Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace's DERM Position: Q1 2026 in Review

Marshall Wace sold out of Journey Medical (DERM) in Q1 2026, closing a stake of 19,401 shares — an estimated $150K sold.

Marshall Wace first reported a position in DERM in Q4 2025 and held it in 1 quarter. The position peaked at $150K in Q4 2025. 71 funds tracked by Wall St. Rank hold DERM as of Q1 2026.

Marshall Wace reported no remaining Journey Medical position as of Q1 2026 after selling out during the quarter.
Marshall Wace sold 19,401 Journey Medical shares in Q1 2026, an estimated $150K.
Marshall Wace first reported a position in Journey Medical in Q4 2025 and held it in 1 quarter.
Marshall Wace's Journey Medical position peaked at $150K in Q4 2025.
71 funds tracked by Wall St. Rank held Journey Medical as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.